Clinical trial · Interventional
Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions
Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions
NCT01583816CI-TRIAL-00020205completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Actinic Keratosis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| placebo | Drug | — | UNRESOLVED |
| Resiquimod 0.01% | Drug | — | UNRESOLVED |
| Resiquimod 0.03% | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- Resiquimod Gel 0.03% or placebo
- description
- Resiquimod gel 0.03% or placebo, once daily, 3x per week for 4 weeks, break of 8 weeks, repeated once
- interventionNames
- Drug: Resiquimod 0.03%
- Drug: placebo
- type
- EXPERIMENTAL
- label
- Resiquimod or placebo
- description
- Once daily, 7x within 2 weeks, break of 8 weeks, cycle repeated once
- interventionNames
- Drug: Resiquimod 0.03%
- Drug: placebo
- type
- EXPERIMENTAL
- label
- Resiquimod or vehicle
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent * Male or nonpregnant, nonlactating female, ≥18 years * A minimum of 2 clinically diagnosed AK-lesions within a defined area (25 cm2 contiguous treatment area). One AK-lesion must have a diameter of at least 6 mm (indicator lesion) * AK-lesions on balding scalp, forehead or face Exclusion Criteria: * Known allergy or hypersensitivity to any of the trial gel ingredients * Dermatological disease or condition that might be exacerbated by resiquimod gel treatment or may impair trial assessments * Evidence of unstable or uncontrolled clinically significant medical conditions, active infection, immunosuppression or systemic cancer
References
Publications (0)
Data not yet available
No reference posted for this study.